Related Experiment Video
Updated: Jun 14, 2025
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
12.0K
Tirofiban Combination Therapy for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Abdullah Bin Kamran1, Ahmed Bazil Bin Khalil2, Ayesha Muhammad1
1Rawalpindi Medical University, Rawalpindi, Pakistan.
Brain and Behavior
|June 11, 2025
Summary
Tirofiban improves outcomes for acute ischemic stroke (AIS) patients by enhancing functional recovery and reducing neurological deficits. This glycoprotein IIb/IIIa inhibitor does not increase the risk of symptomatic intracranial hemorrhage (sICH).
Area of Science:
- Neuroscience
- Cardiology
- Pharmacology
Background:
- Acute ischemic stroke (AIS) is a significant global health burden.
- Standard antiplatelet therapies offer incomplete protection against recurrent thrombotic events.
- Tirofiban, a glycoprotein IIb/IIIa inhibitor, is explored as an adjunctive treatment for AIS.
Purpose of the Study:
- To evaluate the efficacy and safety of tirofiban as an adjunct to standard antiplatelet therapy in AIS patients.
- To assess the impact of tirofiban on functional outcomes, neurological impairment, and hemorrhage risk.
Main Methods:
- A systematic review and meta-analysis of randomized controlled trials (RCTs) and comparative observational studies.
- Searched databases (PubMed, ClinicalTrials.gov, Cochrane) up to July 2024 following PRISMA guidelines.
- Analyzed outcomes including modified Rankin Scale (mRS), National Institute of Health Stroke Scale (NIHSS), symptomatic intracranial hemorrhage (sICH), and mortality.
Main Results:
- Fifteen studies involving 4,457 patients were included.
- Tirofiban significantly improved favorable mRS scores (OR 1.65, p=0.0001) and reduced NIHSS scores (MD -2.08, p<0.00001).
- No significant increase in symptomatic intracranial hemorrhage (sICH) was observed.
Conclusions:
- Tirofiban as an adjunct to standard antiplatelet therapy improves functional outcomes in AIS patients.
- Tirofiban effectively reduces neurological impairment without elevating the risk of intracranial hemorrhage.
- This meta-analysis supports tirofiban's role in managing AIS.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
652
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
652